Advancement in the management of Von Hippel Lindau (VHL) Disease: A Comprehensive Educational Program on hypoxia-inducible factor-2 alpha inhibitor (HIF-2a)
Type
Webinar
EVENT DETAILS
Display Date
Wednesday May 8, 2024
Display Date Line 2
8 pm ET
Location
Virtual
Speaker
Chair: Simon Tanguay // Speakers: Shereen Ezzat & Maryam Soleimani
ACCREDITATION
Accreditation
Section 1 Group Learning Credits
Event Description
Chair: Simon Tanguay
Speakers: Shereen Ezzat & Maryam Soleimani
OBJECTIVES
By participating in this learning program, healthcare providers can expect to:
- Discuss the mechanism of action of HIF-2α inhibitors in suppressing tumor growth in VHL-related tumors.
- Examine the clinical efficacy and safety profile of HIF-2α inhibitors and impact on clinical practice.
- Explore strategies for early identification and management of side effects associated with HIF-2α inhibitors, based on evidence-based medicine and lessons learned from real-world experience.
Simultaneous interpretation from English to French will be available
Footer
ACCREDITATION
This activity is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by CUA. You may claim a maximum of 1 hour of credit.
_______________________________________________________
Sponsored:
